Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all

Pagliusi, Sonia; Leite, Luciana C. C.; Datla, Mahima; Makhoana, Morena; Gao, Yongzhong; Suhardono, Mahendra; Jadhav, Suresh; Harshavardhan, G.; Homma, Akira

doi:10.1016/j.vaccine.2012.11.060

Cited by 28 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These initiatives have partly been driven by the expanding network of vaccine manufacturers in the emerging economies, particularly India (BioMed, Shantha Biotechnics and Bharat Biotech International) and China (Lanzhou Institute of Biological Products). Several other manufacturers in the Developing Countries Vaccine Manufacturers Network, 159 such as the Finlay Institute, Biological E, Biofarma, Chengdu, SK Chemical and EuBiologics are also developing vaccines against Salmonella . Impetus for the development of Salmonella vaccines has also come from global health vaccine institutes, particularly the International Vaccine Institute (IVI) 160 in Seoul, South Korea, and Novartis Vaccines Institute for Global Health (NVGH) 161 in Siena, Italy, as well as key academic institutions, notably the National Institutes of Health, USA, and Center for Vaccine Development (CVD) at the University of Maryland, Baltimore, USA.…”

Section: New Vaccinesmentioning

confidence: 99%

Vaccines against invasiveSalmonelladisease

MacLennan¹,

Martin

Micoli

2014

Human Vaccines & Immunotherapeutics

168

128

View full text Add to dashboard Cite

Though primarily enteric pathogens, Salmonellae are responsible for a considerable yet under-appreciated global burden of invasive disease. In South and South-East Asia, this manifests as enteric fever caused by serovars Typhi and Paratyphi A. In sub-Saharan Africa, a similar disease burden results from invasive nontyphoidal Salmonellae, principally serovars Typhimurium and Enteritidis. The existing Ty21a live-attenuated and Vi capsular polysaccharide vaccines target S. Typhi and are not effective in young children where the burden of invasive Salmonella disease is highest. After years of lack of investment in new Salmonella vaccines, recent times have seen increased interest in the area led by emerging-market manufacturers, global health vaccine institutes and academic partners. New glycoconjugate vaccines against S. Typhi are becoming available with similar vaccines against other invasive serovars in development. With other new vaccines under investigation, including live-attenuated, protein-based and GMMA vaccines, now is an exciting time for the Salmonella vaccine field.

show abstract

Section: New Vaccinesmentioning

confidence: 99%

Vaccines against invasiveSalmonelladisease

MacLennan¹,

Martin

Micoli

2014

Human Vaccines & Immunotherapeutics

168

128

View full text Add to dashboard Cite

show abstract

“…The Developing Countries Vaccine Manufacturers Network (DCVMN) is a unique model of a public and private international alliance [91,92] that has achieved a significant and continuous growth over the last 15 years, counting today 45 members from 16 countries, not including any multinational company or subsidiary. Although, its first aim is to provide a consistent and sustainable supply of quality vaccines at an affordable price to developing countries, its members are also striving to accelerate the production of innovative vaccines, conceiving technology transfer and co-development as one of the most effective ways to do it [91].…”

Section: Discussionmentioning

confidence: 99%

Plant-Based Vaccine for Livestock: Key Points to Unleash Platform Translation in Developing Countries

Aguirreburualde¹,

Petruccelli

Almonacid

et al. 2016

Curr Mol Bio Rep

View full text Add to dashboard Cite

Purpose of review Ten years ago the first plant-based vaccine was licensed (DowAgrosciences). It was only 20 years after the first report of a recombinant protein obtained through plant transformation technology. Back then, this vaccine was perceived as the first of an unlimited list of innovative products of a flourishing platform. Unexpectedly, since then, no other veterinary product based on plant molecular pharming (PMP) has reached the market. This review will reflect a transdisciplinary view of the status and challenges that the molecular farming platform faces to become a strategic solution for the agroindustrial sector of developing countries. Recent findings Plant-based veterinary vaccines (PBVV) have the potential to give answers to several challenges that animal health presents today. The urgent need to improve livestock productivity, especially in low and middle-income countries (LMIC), and the current concern about the emergence of antimicrobial resistance associated with animal production, demands new products such as inexpensive vaccines and therapeutics. Based on the translational research scheme, certain barriers that could have limited the development into products of many results obtained in the last 15 years were identified. Summary Unquestionably, the development of innovation in LMIC is a key element in the feasibility of the platform. The emergence of PPP between multiple stakeholders as a strategy to overcome the existing disconnection between academia and industry, could enable the conversion of leading vaccine candidates from the stage of proof of concept into prototypes for industry, and thereby foster 'productization' in the field of veterinary vaccines. Keywords Innovation. Livestock. Molecular farming. Plant-based vaccines. Translational research This article is part of the Topical Collection on Enhancing Agricultural Production

show abstract

“…Many are relatively newly established and may have limited experience and/or expertise, especially in highly subspecialized biotechnologies (24, 25). Once pre-qualified by WHO, manufacturers in these countries are now providing much of the vaccines used globally (31). The NRA's providing oversight over these manufacturers may need technical assistance to ensure these vaccines meet good manufacturing practice and other global standards.…”

Section: Opportunities To Enhance Vaccine Safety In Regulatory Setmentioning

confidence: 99%

Enhancing vaccine safety capacity globally: A lifecycle perspective

Chen

Shimabukuro

Martín

et al. 2015

Vaccine

View full text Add to dashboard Cite

Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th Century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved in the future to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a “lifecycle” approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle- income countries.

show abstract

Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all

Cited by 28 publications

References 18 publications

Vaccines against invasiveSalmonelladisease

Vaccines against invasiveSalmonelladisease

Plant-Based Vaccine for Livestock: Key Points to Unleash Platform Translation in Developing Countries

Enhancing vaccine safety capacity globally: A lifecycle perspective

Contact Info

Product

Resources

About